Q2
AARD — Q2 2026 Financial Report Analysis
With ARD-101 on FDA clinical hold and its Phase 3 HERO trial terminated, Aardvark's Q2 net loss held at $14.4M as trial spending fell, while cash dropped to $73.9M and the runway was extended to late 2027 through spending cuts.